Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy
Pirker I, Rubbert-Roth A, von Kempis J, Fehr M, Neumann T. Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy. Clin Exp Rheumatol 2020
28.01.2020Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy
28.01.2020Clin Exp Rheumatol 2020
Pirker Ian, Rubbert-Roth Andrea, von Kempis Johannes, Fehr Martin, Neumann Thomas
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
Omlin A, Ryan C, Rubin M, Roach M, Reiter R, Pritchard C, Poon D, Parker C, Padhani A, O'Sullivan J, Ost P, Oh W, Murthy V, Murphy D, Mrabti H, Mottet N, Morris M, Saad F, Sade J, Zapatero A, van Oort I, Türkeri L, Tombal B, Taplin M, Sydes M, Sweeney C, Suzuki H, Steuber T, Sternberg C, Soule H, Smith M, Small E, Shore N, Scher H, Sartor O, Morgans A, Millman R, Evans C, Efstathiou E, Eeles R, Duran I, Drake C, de Bono J, Davis I, Clarke N, Chi K, Bristow R, Briganti A, Bossi A, Bjartell A, Beltran H, Beer T, Attard G, Fanti S, Feng F, Maluf F, Logothetis C, Leibowitz R, Khauli R, Kantoff P, Kanesvaran R, James N, Hussain M, Hofman M, Higano C, Heinrich D, Heidenreich A, Halabi S, Gleave M, Frydenberg M, Fizazi K, Gillessen S. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol 2020; 77:508-547.
27.01.2020Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
27.01.2020Eur Urol 2020; 77:508-547
Omlin Aurelius, Ryan Charles J, Rubin Mark, Roach Mack, Reiter Robert E, Pritchard Colin C, Poon Darren M C, Parker Chris, Padhani Anwar R, O'Sullivan Joe M, Ost Piet, Oh William K, Murthy Vedang, Murphy Declan G, Mrabti Hind, Mottet Nicolas, Morris Michael J, Saad Fred, Sade Juan Pablo, Zapatero Almudena, van Oort Inge, Türkeri Levent, Tombal Bertrand, Taplin Mary-Ellen, Sydes Matthew R, Sweeney Christopher, Suzuki Hiroyoshi, Steuber Thomas, Sternberg Cora N, Soule Howard, Smith Matthew, Small Eric, Shore Neal, Scher Howard I, Sartor Oliver, Morgans Alicia K, Millman Robin, Evans Christopher P, Efstathiou Eleni, Eeles Ros, Duran Ignacio, Drake Charles G, de Bono Johann, Davis Ian D, Clarke Noel, Chi Kim N, Bristow Rob G, Briganti Alberto, Bossi Alberto, Bjartell Anders, Beltran Himisha, Beer Tomasz M, Attard Gerhardt, Fanti Stefano, Feng Felix Y, Maluf Fernando, Logothetis Chris, Leibowitz Raya, Khauli Raja B, Kantoff Philip, Kanesvaran Ravindran, James Nicolas, Hussain Maha, Hofman Michael S, Higano Celestia Tia S, Heinrich Daniel, Heidenreich Axel, Halabi Susan, Gleave Martin, Frydenberg Mark, Fizazi Karim, Gillessen Silke
Akutes Karpaltunnelsyndrom durch Thrombose einer persistierenden Arteria mediana
Baumer A, Hundsberger T. Akutes Karpaltunnelsyndrom durch Thrombose einer persistierenden Arteria mediana. Swiss Medical Forum 2020; 20:86-88.
27.01.2020Akutes Karpaltunnelsyndrom durch Thrombose einer persistierenden Arteria mediana
27.01.2020Swiss Medical Forum 2020; 20:86-88
Baumer Andrea, Hundsberger Thomas
Does progress achieved in the treatment of patients with metastatic non-small-cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland
Schmid S, Suipyte J, Herrmann C, Mousavi M, Hitz F, Früh M. Does progress achieved in the treatment of patients with metastatic non-small-cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland. Eur J Cancer Care (Engl) 2020; 29:e13206.
21.01.2020Does progress achieved in the treatment of patients with metastatic non-small-cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland
21.01.2020Eur J Cancer Care (Engl) 2020; 29:e13206
Schmid Sabine, Suipyte Jorune, Herrmann Christian, Mousavi Mohsen, Hitz Felicitas, Früh Martin
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
Metaxas Y, von Moos R, Rauch D, Appenzeller C, Waibel C, Schmid S, Froesch P, Biaggi-Rudolf C, Perrino M, Maconi A, Schneider M, Mark M, Ceresoli G, Zucali P, Pless M, Grosso F, Eboulet E, Früh M, Swiss Group for Clinical Cancer Research (SAKK). Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). Ann Oncol 2020; 31:495-500.
16.01.2020Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
16.01.2020Ann Oncol 2020; 31:495-500
Metaxas Y, von Moos R, Rauch D, Appenzeller Christina, Waibel C, Schmid S, Froesch P, Biaggi-Rudolf C, Perrino M, Maconi A, Schneider M, Mark M, Ceresoli G L, Zucali P A, Pless M, Grosso F, Eboulet E I, Früh Martin, Swiss Group for Clinical Cancer Research (SAKK)
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Karn T, Schem C, Young B, Hanusch C, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Gerber B, Holtrich U, Müller V, Meissner T, Weber K, Solbach C, Denkert C, Engels K, Fasching P, Sinn B, Schrader I, Budczies J, Marme F, Loibl S. A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. Clin Cancer Res 2020; 26:1896-1904.
13.01.2020A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
13.01.2020Clin Cancer Res 2020; 26:1896-1904
Karn Thomas, Schem Christian, Young Brandon M, Hanusch Claus, Stickeler Elmar, Huober Jens, van Mackelenbergh Marion, Leyland-Jones Brian, Fehm Tanja, Nekljudova Valentina, Untch Michael, Gerber Bernd, Holtrich Uwe, Müller Volkmar, Meissner Tobias, Weber Karsten E, Solbach Christine, Denkert Carsten, Engels Knut, Fasching Peter A, Sinn Bruno V, Schrader Iris, Budczies Jan, Marme Frederik, Loibl Sibylle
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
Khoo V, N'Dow J, Necchi A, Neuzillet Y, Oddens J, Oldenburg J, Osanto S, Oyen W, Pacheco-Figueiredo L, Pappot H, Patel M, Pieters B, Plass K, Remzi M, Müller C, Müller A, Kiltie A, Krege S, Ladoire S, Lara P, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Carmen Mir M, Moschini M, Mostafid H, Retz M, Richenberg J, Turkbey B, Vahr Lauridsen S, Valdagni R, Van Der Heijden A, Van Poppel H, Vartolomei M, Veskimäe E, Vilaseca A, Vives Rivera F, Wiegel T, Wiklund P, Williams A, Zigeuner R, Tombal B, Thalmann G, Rink M, Roghmann F, Rosenberg J, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk R, Smits A, Stenzl A, Witjes J, Kamat A, Horwich A, Arends T, Bamias A, Birtle A, Black P, Bochner B, Bolla M, Boormans J, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Agarwal N, Xylinas E, Babjuk M, Bellmunt J, Bruins H, De Reijke T, De Santis M, Gillessen Sommer S, James N, Maclennan S, Palou J, Powles T, Ribal M, Shariat S, van der Kwast T, Chiti A, Choudhury A, Gontero P, Grubmüller B, Hafeez S, Hansel D, Hartmann A, Hayne D, Henry A, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa B, Geavlete B, Gakis G, Compérat E, Crabb S, Culine S, De Bari B, DeBlok W, De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig J, Fanti S, Fonteyne V, Frydenberg M, Futterer J, Jones R. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Ann Oncol 2020; 30:1697-1727.
08.01.2020EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
08.01.2020Ann Oncol 2020; 30:1697-1727
Khoo V, N'Dow J, Necchi A, Neuzillet Y, Oddens J R, Oldenburg J, Osanto S, Oyen W J G, Pacheco-Figueiredo L, Pappot H, Patel M I, Pieters B R, Plass K, Remzi M, Müller C R, Müller A-C, Kiltie A E, Krege S, Ladoire S, Lara P C, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Carmen Mir M, Moschini M, Mostafid H, Retz M, Richenberg J, Turkbey B, Vahr Lauridsen S, Valdagni R, Van Der Heijden A G, Van Poppel H, Vartolomei M D, Veskimäe E, Vilaseca A, Vives Rivera F A, Wiegel T, Wiklund P, Williams A, Zigeuner R, Tombal B, Thalmann G N, Rink M, Roghmann F, Rosenberg J E, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk R J, Smits A, Stenzl A, Witjes J A, Kamat A M, Horwich A, Arends T, Bamias A, Birtle A, Black P C, Bochner B H, Bolla M, Boormans J L, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Agarwal N, Xylinas E, Babjuk M, Bellmunt J, Bruins H M, De Reijke T M, De Santis M, Gillessen Sommer Silke, James N, Maclennan S, Palou J, Powles T, Ribal M J, Shariat S F, van der Kwast T, Chiti A, Choudhury A, Gontero P, Grubmüller B, Hafeez S, Hansel D E, Hartmann A, Hayne D, Henry A M, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa B A, Geavlete B, Gakis G, Compérat E, Crabb S, Culine S, De Bari B, DeBlok W, De Visschere P J L, Decaestecker K, Dimitropoulos K, Dominguez-Escrig J L, Fanti S, Fonteyne V, Frydenberg M, Futterer J J, Jones R
Perioperative treatment of soft-tissue sarcoma
Rothermundt C. Perioperative treatment of soft-tissue sarcoma. memo - Magazine of European Medical Oncology 2020
07.01.2020Perioperative treatment of soft-tissue sarcoma
07.01.2020memo - Magazine of European Medical Oncology 2020
Rothermundt Christian
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
Aeppli S, Sternberg C, Schmidinger M, Rini B, Porta C, Omlin A, Oldenburg J, McDermott D, Gruenwald V, Larkin J, Fischer S, Escudier B, Eisen T, Eboulet E, Rothermundt C. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. ESMO Open 2020; 5
01.01.2020Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
01.01.2020ESMO Open 2020; 5
Aeppli Stefanie, Sternberg Cora, Schmidinger Manuela, Rini Brian, Porta Camillo, Omlin Aurelius, Oldenburg Jan, McDermott David, Gruenwald Viktor, Larkin James, Fischer Stefanie, Escudier Bernard, Eisen Tim, Eboulet Eric Innocents, Rothermundt Christian
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
Massa C, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P, Untch M, Loibl S, Weber K, Huober J, Marme F, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer J, Zahm D, Jackisch C, van Mackelenbergh M, Thomalla J, Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer 2020; 8
01.01.2020Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
01.01.2020J Immunother Cancer 2020; 8
Massa Chiara, Müller Volkmar, Schem Christian, Mueller Anja, Stickeler Elmar, Biehl Katharina, Fasching Peter A, Untch Michael, Loibl Sibylle, Weber Karsten, Huober Jens, Marme Frederik, Karn Thomas, Denkert Carsten, Schneeweiss Andreas, Hanusch Claus, Blohmer Jens-Uwe, Zahm Dirk-Michael, Jackisch Christian, van Mackelenbergh Marion, Thomalla Jörg, Seliger Barbara
Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma
Favara D, Larkin J, Powell N, Turajlic S, Chauhan D, Diem S, Daniels E, Clark J, Au L, Spain L, Yousaf N. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open 2020; 5
01.01.2020Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma
01.01.2020ESMO Open 2020; 5
Favara David M, Larkin James M, Powell Nick, Turajlic Samra, Chauhan Dharmisha, Diem Stefan, Daniels Ella, Clark James, Au Lewis, Spain Lavinia, Yousaf Nadia
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
Burstein H, Thürlimann B, Winer E, Senn H, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsky P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 2019; 30:1541-1557.
27.12.2019Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
27.12.2019Ann Oncol 2019; 30:1541-1557
Burstein H J, Thürlimann Beat, Winer E P, Senn H-J, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsky P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019
Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma
Fischer S, Langberg C, Ståhl O, Fankhauser C, Hamid A, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen Sommer S, Wheater M, Hentrich M, Heidenreich A, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Global Germ-Cell Cancer Group. Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. J Clin Oncol 2019:JCO1901876.
26.12.2019Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma
26.12.2019J Clin Oncol 2019:JCO1901876
Fischer Stefanie, Langberg Carl W, Ståhl Olof, Fankhauser Christian Daniel, Hamid Anis A, Koutsoukos Konstantinos, Shamash Jonathan, White Jeff, Bokemeyer Carsten, Beyer Jörg, Gillessen Sommer Silke, Wheater Matthew, Hentrich Marcus, Heidenreich Axel, Tandstad Torgrim, Cohn-Cedermark Gabriella, Thibault Constance, Vincenzi Bruno, Klingbiel Dirk, Albany Costantine, Necchi Andrea, Terbuch Angelika, Lorch Anja, Aparicio Jorge, Global Germ-Cell Cancer Group
Progress in therapy across the spectrum of advanced prostate cancer
Schmid S, Omlin A. Progress in therapy across the spectrum of advanced prostate cancer. Nat Rev Urol 2019
16.12.2019Progress in therapy across the spectrum of advanced prostate cancer
16.12.2019Nat Rev Urol 2019
Schmid Sabine, Omlin Aurelius
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
Mark M, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Ribi K, Thürlimann B, von Moos R. Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16). J Bone Oncol 2019; 21:100273.
16.12.2019Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
16.12.2019J Bone Oncol 2019; 21:100273
Mark Michael, Caspar Clemens B, Mannhart Meinrad, von Burg Philipp, Blum Veronika, Bohanes Pierre, Anchisi Sandro, von Briel Thomas, Zürrer-Härdi Ursina, Cathomas Richard, Dietrich Daniel, Schär Corinne, Ribi Karin, Thürlimann Beat, von Moos Roger
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Hamzic S, Amstutz U, López-Fernández L, García-González X, Schellens J, Meulendijks D, Thomlinson I, Palles C, Aebi S, Jörger M, Froehlich T, Kummer D, Largiadèr C. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. Pharmacol Res 2019; 152:104594.
12.12.2019Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
12.12.2019Pharmacol Res 2019; 152:104594
Hamzic Seid, Amstutz Ursula, López-Fernández Luis A, García-González Xandra, Schellens Jan H M, Meulendijks Didier, Thomlinson Ian, Palles Claire, Aebi Stefan, Jörger Markus, Froehlich Tanja K, Kummer Dominic, Largiadèr Carlo R
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
Risi E, Di Leo A, Biganzoli L, Sotiriou C, Vitale S, Boccalini G, Romagnoli D, Huober J, Di Cosimo S, Hilbers F, Guarducci C, Bonechi M, McCartney A, Migliaccio I, Benelli M, Biagioni C, Malorni L. An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Ther Adv Med Oncol 2019; 11:1758835919891608.
11.12.2019An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
11.12.2019Ther Adv Med Oncol 2019; 11:1758835919891608
Risi Emanuela, Di Leo Angelo, Biganzoli Laura, Sotiriou Christos, Vitale Stefania, Boccalini Giulia, Romagnoli Dario, Huober Jens, Di Cosimo Serena, Hilbers Florentine, Guarducci Cristina, Bonechi Martina, McCartney Amelia, Migliaccio Ilenia, Benelli Matteo, Biagioni Chiara, Malorni Luca
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
Sinn B, Denkert C, Seliger B, von Minckwitz G, Huober J, Ataseven B, Stickeler E, Schem C, Marme F, Klauschen F, Taube E, Karn T, Blohmer J, Symmans W, Fasching P, Schmitt W, Weber K, Loibl S. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Res 2019; 21:142.
11.12.2019Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
11.12.2019Breast Cancer Res 2019; 21:142
Sinn Bruno Valentin, Denkert Carsten, Seliger Barbara, von Minckwitz Gunter, Huober Jens, Ataseven Beyhan, Stickeler Elmar, Schem Christian, Marme Frederik, Klauschen Frederick, Taube Eliane Tabea, Karn Thomas, Blohmer Jens-Uwe, Symmans William Fraser, Fasching Peter A, Schmitt Wolfgang Daniel, Weber Karsten E, Loibl Sibylle
Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis
Brenig R, Antoniades C, Wendon J, Heim M, Ludewig B, Weston C, Duong F, Semela D, Brand S, Boldanova T, Künzler-Heule P, Cupovic J, Besse L, Pérez Shibayama C, Singanayagam A, Geng A, Triantafyllou E, Pop O, Bernsmeier C. Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis. Life Sci Alliance 2019; 3
10.12.2019Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis
10.12.2019Life Sci Alliance 2019; 3
Brenig Robert, Antoniades Charalambos G, Wendon Julia, Heim Markus H, Ludewig Burkhard, Weston Christopher J, Duong François Ht, Semela David, Brand Stephan, Boldanova Tuyana, Künzler-Heule Patrizia, Cupovic Jovana, Besse Lenka, Pérez Shibayama Christian Ivan, Singanayagam Arjuna, Geng Anne, Triantafyllou Evangelos, Pop Oltin, Bernsmeier Christine
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
Schneeweiss A, Lagkadinou E, Wilkinson G, Boix O, Thiele S, Rudolph M, Rentzsch C, Hurvitz S, Ma C, Tsimberidou A, Moulder S, Varga A, Jörger M, Hess D, Ocker M. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers (Basel) 2019; 11
10.12.2019Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
10.12.2019Cancers (Basel) 2019; 11
Schneeweiss Andreas, Lagkadinou Eleni, Wilkinson Gary, Boix Oliver, Thiele Silke, Rudolph Marion, Rentzsch Christine, Hurvitz Sara A, Ma Cynthia, Tsimberidou Apostolia M, Moulder Stacy, Varga Andrea, Jörger Markus, Hess Dagmar, Ocker Matthias